Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.

@article{Tack2009PrucaloprideI,
  title={Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.},
  author={Jan Tack and M J Van Outryve and Greet Beyens and Ren{\'e} Kerstens and Lieve Vandeplassche},
  journal={Gut},
  year={2009},
  volume={58 3},
  pages={357-65}
}
OBJECTIVE To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT(4) receptor agonist, in patients with chronic constipation. METHODS In this multicentre, randomised, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/week) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 weeks. The primary efficacy endpoint was the… CONTINUE READING